Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience

References

• HoweHLWingoPAThunMJAnnual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trendsJ Natl Cancer Cancer Inst200193824842
   PubMed Web of Science ®Google Scholar
• HosseiniMSeyed AlinaghiSAhmoudiMMcFarlandWA case-control study of risk factors for prostate cancer in IranActa Med Iran2010481616621137672
   PubMedGoogle Scholar
• StameyTAYangNHayARMcNealJEFreihaFSRedwineEProstate-specific antigen as a serum marker for adenocarcinoma of the prostaeN Engl J Med19873179099162442609
   PubMed Web of Science ®Google Scholar
• LinKLipsitzRMillerTJanakiramanSBenefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task ForceAnn Intern Med2008149319219918678846
   PubMed Web of Science ®Google Scholar
• OesterlingJEProstate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostateJ Urol19911459079231707989
   PubMed Web of Science ®Google Scholar
• MoslemiMKAbedin ZadehMAA modified technique of simple suprapubic prostatechomy: no bladder drainage and no bladder neck or hemostatic surfacesUrol J201071515520209457
   PubMed Web of Science ®Google Scholar
• BensonMCWhangISPantuckAProstate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancerJ Urol19921478158161371554
   PubMed Web of Science ®Google Scholar
• CatalonaWJRichieJPAhmannFRComparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 menJ Urol1994151128312907512659
   PubMed Web of Science ®Google Scholar
• ParkHKHongSKByunSSLeeSEComparison of the rate of detecting prostate cancer and the pathologic characteristics of the patients with a serum PSA level in the range of 3.0 to 4.0 ng/mL and the patients with a serum PSA level in the range 4.1 to 10.0 ng/mLKorean J Urol200647358361
   Google Scholar
• ChoJMLeeSWKangJYYooTKSafety and efficacy of combined transrectal ultrasound-guided prostate needle biopsy and transurethral resection of the prostateKorean J Urol201051210110520414421
   PubMedGoogle Scholar
• RommelFMAgustaVEBreslinJAThe use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practiceJ Urol199415188937504748
   PubMed Web of Science ®Google Scholar
• DadkhahFSafarinejadMRAminiELashayARBaghayeeAUtility of prostate specific antigen density and free to total prostate specific antigen ratio for detecting prostate cancer in Iranian men: a prospective study of 187 casesCurr Urol2010415
   Google Scholar
• HosseiniSYMoharramzadehMGhadianARHooshyarHLashayARSafarinejadMRPopulation-based screening for prostate cancer by measuring total serum prostate-specific antigen in IranInt J Urol20071440641117511722
   PubMed Web of Science ®Google Scholar
• MostofiFKSesterhennISobinLHHistological typing of prostate tumorsMostofiFKInternational Histological Classification of Tumors No. 22GenevaWorld Health Organization1980126
   Google Scholar
• GleasonDFVeterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinomaTannenbaumMUrologic Pathology: the prostatePhiladelphiaLea & Febiger1977171198
   Google Scholar
• GhafooriMVarediPHosseiniSJAsgariMShakibaMValue of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of menUrol J20096318218819711272
   PubMed Web of Science ®Google Scholar
• MousaviSMToward prostate cancer early detection in IranAsian Pac J Cancer Prev200910341341819640184
   PubMedGoogle Scholar
• MohagheghiMAMosavi-JarrahiRMalekzadehRParkinMCancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998–2001Arch Iran Med2009121152319111024
   PubMed Web of Science ®Google Scholar
• MousaviSMGouyaMMRamazaniRDavanlouMHajsadeghiNSeddighiZCancer incidence and mortality in IranAnn Oncol200920355656319073863
   PubMed Web of Science ®Google Scholar
• AkbariMEHosseiniSJRezaeeAHosseiniMMRezaeeISheikhvatanMIncidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005Asian Pac J Cancer Prev200894 54955219256736
   PubMedGoogle Scholar
• SadjadiAMalekzadehRDerakhshanMHCancer occurrence in Ardabil. Results of a population-based cancer registry from IranInt J Cancer200310711311812925965
   PubMed Web of Science ®Google Scholar
• SafarinejadMRPopulation-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in IranAnn Oncol2006171166117116684791
   PubMed Web of Science ®Google Scholar
• KhezriAAShiraziMAyatollahiSMAge specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian menIran J Immunol200961404819293477
   PubMed Web of Science ®Google Scholar
• MehrabiSGhafarian ShiraziHRastiMBayatBAnalysis of serum prostate-specific antigen levels in men aged 40 years and older in Yasuj, IranUrol J2005218919217602427
   PubMedGoogle Scholar
• AmirrasouliHKazerouniFSanadizadeJAccurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian populationUrol J.2010 10729910420535696
   PubMed Web of Science ®Google Scholar
• CatalonaWJPartinAWSlawinKMUse of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trialJAMA1998279154215479605898
   PubMed Web of Science ®Google Scholar
• KangSHBaeJHParkHSProstate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 casesInt J Urol20061391091416882054
   PubMed Web of Science ®Google Scholar
• YamamotoSKinUNakamuraKTransperineal ultrasoundguided 12-core systematic biopsy of the prostate for patients with a prostate specific antigen level of 2.5–20 ng/mL in JapanInt J Clin Oncol20051011712115864697
   PubMedGoogle Scholar
• OkiharaKKitamuraKOkadaKMikamiKUkimuraOMikiTTen year trend in prostate cancer screening with high prostate specific antigen exposure rate in JapanInt J Urol20081515616018269453
   PubMed Web of Science ®Google Scholar
• SheikhMAl-SaeedOKehindeEOSinanAnimJTAliYUtility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab menInt Urol Nephrol20053772172616362587
   PubMedGoogle Scholar
• LamJSCheungYKBensonMCGoluboffETComparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white menJ Urol200317045145612853797
   PubMed Web of Science ®Google Scholar
• HamashimaCNakayamaTSagawaMSaitoHSobueTThe Japanese guidelines for prostate cancer screeningJpn J Clin Oncol2009396 33935119346535
   PubMed Web of Science ®Google Scholar
• van VugtHABangmaCHRoobolMJShould prostate-specific antigen screening be offered to asymptomatic men?Expert Rev Anticancer Ther20101071043105320645694
   PubMed Web of Science ®Google Scholar
• HuaLXQiaoDSongNHClinical value of prostate specific antigen screening in early detection of prostate cancerZhonghua Zhong Liu Za Zhi200931970570920021870
   PubMedGoogle Scholar
• GohjiKNomiMEgawaSDetection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrationsCancer19977910196919769149025
   PubMed Web of Science ®Google Scholar